Summit Therapeutics Inc.
SMMT
$18.22
-$0.69-3.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -921.62M | -746.08M | -240.76M | -221.32M | -196.68M |
| Total Depreciation and Amortization | 126.00K | 104.00K | 87.00K | 89.00K | 97.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 629.43M | 515.59M | 62.43M | 63.64M | 58.95M |
| Change in Net Operating Assets | 22.39M | 23.50M | 5.10M | 15.48M | 24.74M |
| Cash from Operations | -269.67M | -206.88M | -173.14M | -142.11M | -112.89M |
| Capital Expenditure | -507.00K | -494.00K | -557.00K | -139.00K | -127.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 394.84M | 286.28M | -64.55M | -205.20M | -228.13M |
| Cash from Investing | 394.33M | 285.79M | -65.10M | -205.34M | -228.26M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -24.50M | -100.00M | -100.00M | -100.00M | -75.50M |
| Issuance of Common Stock | 44.60M | 290.43M | 488.42M | 481.23M | 487.21M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -619.00K |
| Cash from Financing | 20.10M | 190.43M | 388.42M | 381.23M | 411.09M |
| Foreign Exchange rate Adjustments | 13.00K | 105.00K | 56.00K | -18.00K | 362.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 144.78M | 269.44M | 150.23M | 33.76M | 70.31M |